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Abstract
Background: Continuous intrathecal drug delivery has been shown in open studies to improve
pain and quality of life in those with intractable back pain who have had spinal surgery. There is
limited data on long term effects and and even less for patients with mechanical back pain without
prior spinal surgery.
Methods: We have investigated spinal drug administration systems for patients with failed back
syndrome and chronic mechanical low back pain by patient questionnaire study of the efficacy of
this therapy and a case notes review.
Results: 36 patients (97% of 37 approached) completed questionnaires, 24 with failed back
syndrome and 12 with chronic mechanical low back pain. Recalled pre-treatment levels with
current post-treatment levels of pain and a range of quality of life measures (recorded on 11-point
numerical rating scales) were compared. Pain improved significantly in both groups (Wilcoxan
signed ranks test, p < 0.005). The majority of quality of life measures improved significantly in the
failed back syndrome group (Wilcoxan signed ranks test, p < 0.005) although work interruption
and the effect of pain on sex life did not change. There was a trend towards improvement in the
majority of quality of life measures in the mechanical back pain group but this did not reach
statistical significance due to the smaller numbers in this cohort (p > 0.005, Wilcoxan signed ranks
test with Bonferroni correction).
Diamorphine was used in all 37 patients, bupivacaine in 32, clonidine in 27 and baclofen in 3. The
mean dose of diamorphine increased for the first 2 years but did not change 2–6 years post implant,
averaging 4.5 mg/day. Revision surgery was required in 24% of cases, but reduced to 12% in the
later years of our experience.
Conclusions: We conclude that spinal drug administration systems appear to be of benefit in
alleviating pain in the failed back syndrome and chronic mechanical low back pain but need to be
examined prospectively.
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Background
Low back pain is a common complaint with important so-
cio-economic consequences. A comprehensive 1-year sur-
vey of back pain in the UK found that there were 14
million general practitioner (GP) consultations, 1.6 mil-
lion attendances at outpatient clinics, 1 million attend-
ances at physiotherapy, 100,000 hospital admissions,
30,000 day cases and 24,000 operations. It was estimated
that the delivery of these services cost 480 million pounds
in addition to significant societal costs of lost production
(€3.8 billion) and social benefits (€1.4 billion) [1].
The vast majority of chronic low back pain has no clear
cause and is managed symptomatically. Treatment guide-
lines suggest a multidisciplinary approach starting from
the least invasive treatments [2]. Treatments include a
range of physical, psychological, medical and surgical
therapies, most of which are not clearly substantiated but
appear to help some patients. These still leave a significant
number of patients with back pain and disability.
The discovery of opioid receptors in the spinal cord led to
the rationale for the use of intrathecal morphine for pain
relief in cancer [3]. With the development of implantable,
programmable, continuous drug delivery systems in the
1980s, the use of intraspinal opioids was extended to non-
cancer pain, the commonest of which was back pain; nev-
ertheless, use in such circumstances remains less accepted.
This is related to the different outcomes that are strived for
in non-cancer pain compared with cancer pain with limit-
ed life expectancy. In the case of non-malignant pathology
with normal life expectancy, the multidimensional nature
of pain and its effects on function and psychological vari-
ables such as quality of life and mood are deemed more
important. As a result not only pain relief, but also im-
provements in activities of daily living and psychological
well-being are considered important. There are also con-
cerns about drug tolerance and addiction to opioids in
cases of normal life expectancy. The initial costs of these
therapies are substantial due to capital outlay for the
equipment; however, in the longer term there are cost sav-
ings due to less healthcare use when the duration of the
implantable pump therapy exceeds 12–22 months [4].
Previous studies of implantable drug delivery systems for
patients with back pain have shown benefit [5–7]. How-
ever, these studies were restricted to patients who have
had prior spinal surgery and have the failed back syn-
drome (FBS); follow-up was variable and intrathecal drug
therapy was mostly limited to opioids alone.
There is a need to define the place of this therapy in those
patients with mechanical low back pain without prior sur-
gery (LBP), in addition to those with FBS, to evaluate the
place of intrathecal adjuvant analgesics and to measure
these effects over a prolonged time period when consider-
ing a non-terminal condition.
We have been implanting intrathecal pumps delivering
opioid and adjuvant analgesics for chronic back pain in-
cluding patients without prior spinal surgery at our insti-
tution since 1991. We present our experience in terms of
the long term effects of this therapy upon (a) pain relief,
functioning, quality of life and psychological well-being,
as well as (b) drug tolerance and adverse effects.
Methods
We contacted those patients who had a spinal drug ad-
ministration system implanted at our pain centre. Patients
are selected for this therapy after multidimensional pain
assessment and failure to respond to simpler measures in-
cluding physical, psychological, pharmacological and epi-
dural and facet joint injection therapies. We included only
those patients who continued to have the pump refilled
by us. This excluded less than 10% of all patients who had
been referred from distant hospitals and had their refills
elsewhere. We excluded patients whose pumps were im-
planted in the last 6 months and sampled only those with
a diagnosis of non-malignant back pain.
The sample of patients sent a questionnaire numbered 37,
of whom 36 replied (97% response). The mean age of the
responding patients was 54.80 ± 10.00 years; 17 (47%)
were male and 19 (53%) female. The duration of pain
complaint prior to the questionnaire was 13.50 years
(range 7–35). The spinal implant had been in place for a
mean of 4.38 years (range 0.50–9.00). The majority of the
pumps used were SynchroMed (Medtronic). At the start of
our implant program, Cordis Secor patient-activated
pumps were used. In this present sample of 36 patients,
10 had had Cordis Secor pumps implanted, of whom 8
had been subsequently replaced by SynchroMed pumps.
Of the 36 patients, 12 had mechanical low back pain
without prior surgery (LBP) and 24 had the failed back
syndrome (FBS). The median number of prior spinal op-
erations in the FBS group was 2 (range 1–11) (Table 1).
Patients were sent a questionnaire requesting ratings of
pain, the primary endpoint and a range of quality of life
measures on 11-point Likert-style numeral rating scales
with 0 being defined as absence of the symptom or no in-
terference with the quality of life measure, and 10 being
defined as maximum imaginable level of the symptom or
maximal imaginable interference with the quality of life
measure [8,9]. Patients were asked to give ratings on all
variables for their current situation (post-treatment) and
their condition as recalled before they had received the
spinal implant (pre-treatment).BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/17
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Pain was investigated both by asking level of pain experi-
enced, the level of pain relief and also the duration of re-
lief in the average day. Pain was also rated on a 4-point
verbal scale of its severity (none, mild, moderate or se-
vere).
Psychological attributes of the pain experience were meas-
ured by investigating levels of depression, overall quality
of life, coping ability and dependency on others. Socio-
logical dimensions were measured by inquiring about in-
terruption to work, social life, sex life, mobility, driving
and housework in a similar fashion.
The questionnaire also requested comments on use of an-
algesics, average number of general practitioner (GP) vis-
its and inquired about satisfaction with the treatment.
The identities of the patient questionnaires were only
known to a third party until the data was analysed. The
identities of the data were then determined and informa-
tion on the patients' diagnosis, spinal implantation and
subsequent care were collected from case records.
Differences between the LBP and FBS groups were calcu-
lated using Mann Whitney U tests and independent sam-
ple t-tests. Compared to the LBP group, the FBS group
reported longer duration since they started experiencing
pain (means 8.89 (2.57 and 15.55 (7.04, respectively;
t(29) = 2.74, P < 0.01) and since implantation (means
2.18 (2.05 and 5.48 (2.85, respectively; t(34) = 3.57, P <
0.001), but did not differ in age (Table 1). No significant
differences existed between these groups on any of the
pain or quality of life questionnaire measures, but as the
groups were at different stages of coping with back pain
they were analysed as separate groups.
Relationships between aspects of the benefits of treatment
were analysed by Spearman's nonparametric correlations.
Differences between pre- and post-treatment scores were
analysed using chi-squared tests, Wilcoxon signed ranks
tests, and paired samples t-tests. A Bonferroni adjustment
to the level of significance was made to account for the
number of tests carried out between pre- and post-treat-
ment scores with significance at p < 0.005.
Results
Response to treatment
Overall, the treatment was considered to be worthwhile
by the patients, with 26 (74% of the valid 35) responding
that it was very worthwhile, 5 (14%) responding that it
was quite worthwhile, 3 (9%) responding that it was ade-
quate and only 1 (3%) responding that it was not worth-
while. The LBP group were on the lower side of these
scores with 7 (64% of the valid 11) responding that it was
very worthwhile, 2 (19%) responding that it was quite
worthwhile, 1 (9%) responding that it was adequate and
this group included the 1 (9%) who responded that it was
not worthwhile.
Analyses of the Spearman's correlations of all pain and
psychosocial questionnaire items across both the FBS and
LBP groups indicate that on average they were only mod-
erately related (within the same time of reference), with a
mean of 0.38 (equivalent to P < 0.05), from a range of
0.00 (NS) - 0.86 (P < 0.001). However, as these variables
were considered to be conceptually independent, further
analyses were carried out on the individual items, rather
than bluntly grouping all scores.
Across all analyses of pre- and post-treatment scores, ben-
eficial change was seen in the majority of cases on most
variables: the median number of detrimental changes per
variable was 2, with a range of 1–5. Tied scores were only
moderately common, with a median number of 5 per var-
iable, from a range of 0–19. For the FBS group, the median
number of detrimental changes per variable was 1, with a
range of 0–4. The median number of ties was 4 per varia-
ble, from a range of 0–14. For the LBP group, the median
Table 1: Patient characteristics
Total Sample LBP FBS
n = 36 n = 12 n = 24
Sex (male:female) 17:19 5:7 12:12
Age mean (SD) (in years) 54.80 (10.00) 56.33 (12.32) 54.00 (8.75)
Pain duration mean (SD) (in years) 13.61 (6.77) 8.89 (2.57) 15.55 (7.04)
Implant duration mean (SD) (in years) 4.38 (3.03) 2.18 (2.05) 5.48 (2.85)
Previous spinal operations median (range) 2 (1–11)
LBP = Low Back Pain (without prior surgery); FBS = Failed Back SyndromeBMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/17
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number of detrimental changes per variable was 0, with a
range of 0–2. The median number of ties was 1 per varia-
ble, from a range of 0–5.
Differences between pre- and post-treatment scores are
shown for the FBS group in Table 2 and for the LBP group
in Table 3.
Table 2: Efficacy of intrathecal implants in failed back syndrome (n between 20 and 24)
Dimension Variable Pre-Treatment 
Median (Quartiles)
Post-Treatment 
Median (Quartiles)
Z Scorea P valueb
Sensory Pain 9.50 (8.00, 10.00) 5.00 (4.00, 6.00) 4.22 <0.00006*
Pain Relief 9.00 (8.00, 10.00) 3.50 (2.75, 6.25) 4.01 <0.00006*
Psychological Depression 9.00 (7.00, 10.00) 4.00 (0.00, 6.00) 4.01 <0.00006*
Quality of Life 10.00 (8.00, 10.00) 5.00 (3.00, 7.75) 3.79 <0.00022*
Coping 8.00 (7.00, 10.00) 5.00 (4.00, 7.00) 3.68 <0.00032*
Dependency 8.00 (6.00, 10.00) 6.00 (3.00, 8.00) 3.09 <0.0027*
Sociological Sleep 9.50 (8.00, 10.00) 6.00 (4.00, 9.00) 3.06 <0.0027*
Work 10.00 (9.75, 10.00) 10.00 (8.25, 10.00) 1.20 0.2301
Social Life 10.00 (9.00, 10.00) 6.50 (4.00, 8.00) 3.25 <0.00137*
Sex Life 9.50 (8.25, 10.00) 8.50 (5.00, 10.00) 2.12 0.0340
Driving 5.00 (2.00, 9.00) 2.00 (0.00, 6.00) 3.32 <0.00097*
Housework 10.00 (8.00, 10.00) 6.00 (4.00, 8.00) 3.83 <0.00014*
Mobility 10.00 (9.00, 10.00) 6.50 (5.25, 9.00) 3.01 <0.0027*
a The Z score is converted from the Wilcoxon signed ranks test. b A Bonferroni adjustment for the number of tests indicates P < 0.005 (0.05/10) 
as significant.
Table 3: Efficacy of intrathecal implants in low back pain with out prior surgery (n between 9 and 11)
Dimension Variable Pre-Treatment 
Median (Quartiles)
Post-Treatment 
Median (Quartiles)
Z Scorea P valueb
Sensory Pain 9.00 (8.00, 10.00) 6.00 (4.00, 6.00) 2.87 0.0041*
Pain Relief 8.00 (6.50, 9.50) 4.00 (1.50, 6.00) 2.54 0.0111
Psychological Depression 8.00 (5.50, 10.00) 5.00 (2.00, 6.00) 2.37 0.0178
Quality of Life 9.50 (8.00, 10.00) 6.50 (3.75, 7.25) 2.68 0.0074
Coping 8.50 (7.75, 10.00) 6.00 (2.50, 7.00) 2.82 0.0048*
Dependency 8.00 (7.00, 9.00) 6.00 (5.75, 6.50) 2.72 0.0065
Sociological Sleep 10.00 (9.00, 10.00) 7.50 (4.50, 9.00) 2.68 0.0074
Work 10.00 (8.50, 10.00) 9.00 (6.50, 10.00) 1.84 0.0658
Social Life 10.00 (9.00, 10.00) 8.00 (6.00, 8.00) 2.71 0.0067
Sex Life 9.50 (7.25, 10.00) 9.00 (4.75, 10.00) 1.09 0.2757
Driving 7.00 (3.00, 8.00) 7.00 (0.00, 8.00) 0.37 0.7114
Housework 9.00 (7.00, 10.00) 6.00 (5.00, 8.00) 1.50 0.1336
Mobility 9.00 (7.00, 10.00) 8.00 (6.00, 8.00) 2.84 0.0045*
a The Z score is converted from the Wilcoxon signed ranks test. b A Bonferroni adjustment for the number of tests indicates P < 0.005 (0.05/10) as 
significant.BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/17
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The FBS group showed significant improved on the major-
ity of measures: pain score on the 11-point system re-
duced from a median of 9.50 to 5 (Wilcoxon W = 276.00,
Z = 4.22, P < 0.00006). Furthermore, verbal assessment of
pain most commonly changed from severe to moderate,
and when these ratings were converted to a 4-point nu-
merical system, the improvement was significant (Wilcox-
on W = 136.00, Z = 3.64, P < 0.0003). Pain relief
interruption on the 11-point system decreased from a me-
dian of 9 to 3.50 (Wilcoxon W = 251.50, Z = 4.07, P <
0.00006).
With respect to the psychological dimension of pain expe-
rience, for the FBS group the effect of pain on depression
reduced from a median of 9 pre-treatment to 4 post-treat-
ment (Wilcoxon W = 249, Z = 4.01, P < 0.00022); on qual-
ity of life from a median of 10 to 5 (Wilcoxon W = 189.00,
Z = 3.79, P < 0.00022); on coping from a median of 8 to
5 (Wilcoxon W = 258.50, Z = 3.68, P < 0.00032); and on
dependency from a median of 8 to 6 (Wilcoxon W =
171.50, Z = 3.09, P < 0.0027).
In the sociological dimension of pain experience, for the
FBS group the effect of pain on sleep reduced from a me-
dian of 9.50 pre-treatment to 6 post-treatment (Wilcoxon
W = 186.50, Z = 3.06, P < 0.0027); on work, there ap-
peared to be no effect, with both medians being 10 (Wil-
coxon W = 26.50, Z = 1.20, exact P = 0.2301); on social
life, the effect reduced from a median of 10 to 6.50 (Wil-
coxon W = 175.50, Z = 3.25, P < 0.00137); on sex life,
there appeared to be no effect, with the median changing
from 9.50 pre-treatment to 8.50 post-treatment (Wilcox-
on W = 86.00, Z = 2.12, exact P = 0.034); on driving, the
effect reduced from a median of 5 to 2 (Wilcoxon W =
105.00, Z = 3.32, P < 0.00097); on housework from a me-
dian of 10 to 6 (Wilcoxon W = 207.00, Z = 3.83, P <
0.00014); and on mobility from a median of 10 to 6.50
(Wilcoxon W = 201.00, Z = 3.01, P = 0.0027).
For the LBP group, there was a significant reduction in
pain score with treatment from a median of 9 to 6 (Wil-
coxan, Z = 2.87, p = 0.0041); however, although quality of
life measurement changes were similar to the failed back
syndrome cohort and showed a trend to improvement
this was not statistically significant (Wilcoxan, p > 0.005).
Although the results for work disruption do not look as
good as for the other aspects (due to the high number of
ties (n = 19 of the 31 valid cases) on this variable), of the
15 patients less than 50 years of age, none were able to
work before receiving the implant, but 4 (27%) were able
to return to work after implantation.
For the FBS group, the number GP visits per month re-
duced significantly from 2.24 pre-treatment to 0.72 post-
treatment (Wilcoxon W = 136.00, Z = 3.53, adjusted P <
0.05), whereas for the LBP group, the median number re-
duced from 2.07 pre-treatment to 0.90 post-treatment,
but again this did not reach significance (Wilcoxon W =
6.00, Z = 1.60, exact P > 0.1).
Pharmacological data
All 37 patients received diamorphine, 32 received bupi-
vacaine, 27 clonidine and 3 baclofen.
The doses of diamorphine over time are shown in Table 4.
There was wide spread and the median dose increased
over the first two to three years after implant. The data we
have beyond this is restricted to the FBS group, for whom
the dose plateaued from two to six years at a median of 4.5
mg/day. Rapidly increasing dose to reach a daily dose of
10 mg/day occurred in 4 patients. Higher diamorphine
doses were used in the FBS group at similar time points
(Table 5).
Table 4: Diamorphine dose median (range) (in mg)
LBP FBS
Years After Implant n = 12 n = 25
1 2.30 (0.75–4.00) 3.10 (0.50–3.75)
2 3.30 (0.75–6.00) 5.20 (0.75–10.00)
3 4.30 (0.75–7.50) 5.30 (0.75–10.00)
4 5.20 (0.75–16.00)
5 5.50 (0.75–16.00)
6 4.90 (0.75–16.00)
LBP = Low Back Pain (without prior surgery); FBS = Failed Back Syn-
drome
Table 5: Comparison of drugs in spinal implant system in LBP and 
FBS
LBP FBS
n = 12 n = 25
Diamorphine n (%) 12 (100) 25 (100)
Bupivacaine n (%) 9 (75) 23 (92)
Clonidine n (%) 8 (67) 19 (76)
Baclofen n (%) 0 (0) 3 (12)
LBP = Low Back Pain (without prior surgery); FBS = Failed Back Syn-
dromeBMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/17
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Complications
There were 10 episodes of revision surgery, due to catheter
problems (3), pump position problems (4), infection (2)
and cerebrospinal fluid leak (1) (Table 6).
There were a total of 5 documented infections after im-
plant (2 of which required surgery, whilst the others man-
aged with antibiotics).
Comparing complications during the first half (4.5 years)
of our experience with the second 4.5 years, revisions fell
from 5 out of 22 to 2 out of 17 and there have been no in-
fections in the second half (chi squared = 7.5, p < 0.01).
Discussion
The pain generators in chronic low back pain are various
and often not clearly definable, but comprise a combina-
tion of nociceptive and neuropathic components. Man-
agement of chronic back pain is thus to an extent
empirical and commonly involves a stepwise progression
from the lowest risk treatments [2]. As a result, patients
who have failed to find relief may eventually come to be
treated on a trial basis with oral opiates; however, a study
of long term oral opioids for low back and neuropathic
pain, found good results in only 16.7% of cases [10]. This
limitation is most obvious in neuropathic pain states,
which are less opioid sensitive [11]. The pathological
changes consequent upon nerve injury such as up-regula-
tion of cholecystokinin receptors shifts the opioid dose-
response curve to the right. Spinal opioid delivery allows
for a higher concentration at the receptors on primary af-
ferents at the dorsal horn than can be achieved by system-
ic administration since the latter is often limited by dose
dependent side effects. In an animal study of neuropathic
pain using the sciatic nerve constriction model, Suzuki et
al. [12] showed that greater analgesia could be achieved
with opioids delivered intrathecally rather than systemi-
cally.
Spinal opioids for low back pain is a therapy of last resort
and is controversial. Tutak et al. [13] reported on concerns
about opiate tolerance with continually increasing doses
over an 18-month period and Paice et al. [5] found a
mean opioid dose of 9.6 mg/day of morphine after only
one year. In contrast, Winkelmuller and Winkelmuller [6]
found a mean dose of 5.6 mg/day of morphine at an aver-
age follow up of 3.4 years and drug tolerance was uncom-
mon. Nevertheless, concerns about opiate tolerance
remain. There is retrospective outcome data that describes
improvements in pain and a range of quality of life meas-
ures with this therapy [5,6,13]; however, this is largely of
modest duration, has not included patients with low back
pain who have not had prior spinal surgery and the vast
majority of patients received spinal opioids alone.
We have a long experience at our institution of implanting
intrathecal drug administration systems for back pain,
with or without prior spinal surgery and of delivering
combinations of drugs that include opiates and adjuvant
analgesics. We evaluated the efficacy of this therapy upon
pain and quality of life and investigated opiate tolerance
and adverse effects. Patients selected for intrathecal drug
implants had failed to gain pain relief with simpler meas-
ures including drugs, physical treatments, psychological
therapies and spinal injections according to the recog-
nised criteria for spinal implantation [2]. We have found
the pain level reduced by 3 or more on an 11-point scale,
a clinically significant amount, with an average implant
duration of 4.38 years. Most of the quality of life measures
recorded showed a clinically significant improvement
with therapy which reached statistical significance in the
cohort with failed back syndrome. The smaller sample
size preventing the majority quality of life effects reaching
statistical significance for the mechanical low back pain
group. Measures of the psychological dimension of pain
experience (depression, quality of life, coping, dependen-
cy on others) all improved in both groups. All reached sta-
tistical significance for the failed back syndrome cohort
but only in the case of coping for the mechanical back
pain group. Measures of the sociological dimension of
pain experience (sleep, social life, driving, housework)
also showed significant improvement, with the exception
of the effect on sex life and work which were not shown to
have been improved. These changes reached statistical sig-
nificance in the failed back syndrome group. However, of
the 15 patients under 50 years old, all of whom had not
worked preceding implant, 4 had since returned to em-
ployment. Thus an externally reliable measure of work
ability improved.
Table 6: Complications of intrathecal pump implant
Period Type of 
Complication
Number of 
Occurrences
1991–1995 (n = 20) Revision surgeries 8
Infections 5
1996–2000 (n = 17) Revision surgeries 2
Infections 0
Total Revision Surgeries (n = 10) Catheter-related 3
Pump-related 4
Infections requir-
ing surgery
2
Cerebrospinal fluid 
leak
1BMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/17
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Diamorphine was used in all our patients and bupi-
vacaine and clonidine used in approximately two thirds.
The median diamorphine dose increased over the first few
years after implant but in those patients with longer term
dosage data, the FBS group, we found that the median
dose did not change significantly between 2 and 6 years
post implant averaging 4.5 mg/day. Only 4 patients
showed a continually rising dose requirement of diamor-
phine to reach 10 mg/day and none had shown evidence
of opiate abuse. Thus we did not find tolerance to diamor-
phine in this patient group to be a common occurrence.
The dose of diamorphine was greater in the FBS group at
comparable time points compared to those without prior
spinal surgery, and there was a significantly greater use of
bupivacaine and clonidine in FBS compared with non-op-
erated low back pain. This may reflect the greater propor-
tion of neuropathically-mediated pain following spinal
surgery, presumably from scar tissue.
There was no significant difference in outcome scores be-
tween those with FBS and those who had not had prior
spinal surgery both showing in pain level and in the ma-
jority of quality of life measures; however, the numbers in
the mechanical back pain group were insufficient for the
majority of quality of life measures to reach statistical sig-
nificance. There are no previous studies including patients
with non-operated low back pain. They comprise an im-
portant group, partly because the condition is common
and often otherwise intractable, but also because the crite-
ria for spinal surgery in this group have narrowed with
time. Indeed in our practice we are seeing more patients
with non-operated low back pain and less with FBS com-
pared with earlier practice.
The overall complication rate requiring revision surgery
was comparable to others [5,6,14]; however, this reduced
significantly with experience.
A retrospective design relies upon patient recall. Several
studies suggest that patients with chronic pain contrast
with those with acute pain in having a more reliable recall
of past pain [15,16] and its affective dimensions [17]. Pa-
tients can over-rate past pain [18] and thus overestimate
benefits of a treatment; however, overestimates seem to
occur particularly when pain measures have increased over
the treatment period which was not the case in this study
[19]. Pain was our primary endpoint, and as a subjective
experience is difficult to measure. Rating scales are com-
monly used for their simplicity and associated compli-
ance. We chose to use numerical rating scales as these
compare favourably against visual analogue and other rat-
ing scales in terms of minimising scoring errors and opti-
mising sensitivity [8].
We included in our questionnaire a range of questions to
cover the sensory, affective and cognitive dimensions of
pain experience. Many of the questionnaires of these di-
mensions are limited by a complexity that diminishes pa-
tient compliance. Our high response rate may have been
achieved with the simpler numerical rating scales we em-
ployed. Similar scales have been found to have high inter-
nal consistency although their validity has not been
properly evaluated [9].
We collected data on the use of health care resources since
overuse of such resources is a reason for referral. In this
area there are no established measures. We used GP visits,
which can involve any interaction even if the original pain
problem is addressed. As such, an unchanged rate of visit-
ing cannot be easily interpreted, but the reduction in GP
visits that we found may be meaningful.
Our results are comparable to those of others. Winkel-
muller and Winkelmuller [6] found greater pain reduction
of just over 50% on a visual analogue scale; however, their
sample was highly selected as a fifth of patients originally
implanted were later explanted due most commonly to
poor pain relief and not included in their assessment.
Paice et al. [5] described a 60% degree of pain relief; how-
ever, this was based upon physician reports of patients
pain relief. Of the fraction of patients they contacted, it
appeared that physicians had overestimated the degree of
pain relief. Others have found improvements in activities
of daily living [5,6]; however, the methods used to assess
these do not allow for closer comparisons.
Other published series used adjuvant analgesics far less
frequently than we have. In Paice et al.'s survey [5], only
19% of cases included a local anaesthetic and none cloni-
dine or baclofen. In Winkelmuller and Winkelmuller's
study [6], clonidine was used in only 2 of the 82 cases. We
have not noted any serious complications with a greater
use of these adjuvant analgesics, and the opioid doses we
have used are considerably lower than in these other stud-
ies, thus the greater use of adjuvant analgesics appears to
have an opioid-sparing effect. Furthermore, opioid toler-
ance has not been a common clinical problem in our ex-
perience.
Pains with a significant neuropathic component appear
opioid responsive in this study which concurs with others
[5]. Indeed, intrathecal use of opioids in this group may
have distinct advantages as it obviates many of the side ef-
fects of systemic opioids that may be required in large dos-
es producing unacceptable side effects.
Spinal analgesia has limitations. In vivo experiments sug-
gest differential sensitivity between supraspinal and spi-
nal sites with the supra being more sensitive possiblyBMC Musculoskeletal Disorders 2002, 3 http://www.biomedcentral.com/1471-2474/3/17
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because multiple synaptic connections are more sensitive
to opioid than oligosynaptic ones [20]. Although with di-
rect spinal application of opioids patients can achieve an-
algesia they may not achieve the dissociation from their
pain with the systemic doses of morphine that were too
low to have a detectable effect at the spinal level. The mul-
tidimensional model of pain draws attention to role of
higher centres as well as the dorsal horn in pain process-
ing and in clinical practice this perhaps explains the vari-
ation in response of patients to systemic compared to
spinal opioids in their pain management and is the basis
of spinal drug testing before committing to long term de-
livery systems.
To our knowledge, this is the longest survey of implanted
intrathecal pumps for pain and the first to address low
back pain without prior surgery. Using a retrospective
questionnaire we have found an improvement in pain
and range of quality of life measures over a prolonged
time averaging 4.38 years (range 0.50–9.00 years). Toler-
ance to intrathecal opioids does not appear to be a signif-
icant problem and the use of bupivacaine and clonidine
together with diamorphine is without complications and
appears to have an opioid-sparing effect. Revision surgery
especially for catheter-related problems continues to be a
common problem with the current technology, but com-
plication rates in our study were dependent upon opera-
tor and unit experience.
Intrathecal drug delivery systems for failed back syndrome
and chronic mechanical low back pain unresponsive to
simpler measures appears a reasonable therapeutic op-
tion, but there is need to confirm this in prospective ran-
domised controlled trials.
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